Merck & Company Inc (MRK)vsOmnicell Inc (OMCL)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
OMCL
Omnicell Inc
$32.79
+1.67%
HEALTHCARE · Cap: $1.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 5240% more annual revenue ($66.57B vs $1.25B). MRK leads profitability with a 4.8% profit margin vs 3.1%. MRK appears more attractively valued with a PEG of 2.64. OMCL earns a higher WallStSmart Score of 52/100 (C-).
MRK
Hold36
out of 100
Grade: F
OMCL
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for OMCL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Earnings expanding 333.3% YoY
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Smaller company, higher risk/reward
ROE of 1.6% — below average capital efficiency
3.1% margin — thin
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : OMCL
The strongest argument for OMCL centers on Price/Book, EPS Growth, Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : OMCL
The primary concerns for OMCL are Market Cap, Return on Equity, Profit Margin. A P/E of 40.9x leaves little room for execution misses. Thin 3.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
OMCL carries more volatility with a beta of 0.97 — expect wider price swings.
OMCL is growing revenue faster at 7.5% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
OMCL scores higher overall (52/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Omnicell Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Omnicell, Inc., provides medication management automation solutions and adherence tools for health care systems and pharmacies in the United States and internationally. The company is headquartered in Mountain View, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?